Sri Lanka’s pharmaceutical manufacturing industry is approaching an important turning point as a major private-sector investment in the Bingiriya Investment Zone moves towards completion. However, the real test of the project will not be the size of the factory or the investment announced, but whether it can substantially reduce the country’s dependence on imported medicines, conserve foreign exchange and make essential drugs more affordable to ordinary people.
Synergy Pharmaceuticals Corporation (Private) Limited is developing what is described as Sri Lanka’s largest Western pharmaceutical manufacturing facility. The project originated with a Board of Investment (BOI) agreement signed in October 2019, followed by construction commencing in March 2020, with an initial investment commitment of US$16 million.
The facility has now entered its final construction stages, with machinery installation and the development of its Research and Development laboratory progressing. Deputy Minister of Health Hansaka Wijemuni recently inspected the site, while the Ministry of Health has pledged administrative and institutional support to accelerate its commercial launch.
The proposed manufacturing capacity is particularly significant because Sri Lanka continues to import approximately 85%–90% of its pharmaceutical requirements. An EconomyNext report estimated that pharmaceutical imports amounted to US$667 million in 2025, demonstrating the considerable foreign-exchange burden created by the country’s dependence on overseas suppliers.
Synergy expects its facility to eventually meet up to 25% of domestic medicine demand. Its planned product portfolio includes tablets, capsules, injectables, cancer treatments and hormonal medicines. The integrated R&D laboratory is also expected to strengthen local formulation capabilities and quality control.
If the projected production capacity is achieved, the investment could make a meaningful contribution towards reducing imports. Nevertheless, the proposed 25% contribution must be assessed against actual annual production, domestic consumption, product registrations and the extent to which locally manufactured medicines replace existing imports.
Another important development is the completion of Sri Lanka’s first insulin manufacturing facility at the Koggala Export Processing Zone. Premium International Injectable (Pvt) Ltd has invested more than Rs.3 billion, with commercial production expected in 2027 following validation. Its initial plans include insulin, anaesthetics and painkillers, eventually expanding to 33 medicine varieties.
Meanwhile, Sunshine Healthcare and India’s Zydus Lifesciences have embarked on a US$20 million oral solid dosage manufacturing project in Horana, with commercial operations expected in 2028.
These investments coincide with the Government’s National Medicinal Drug Policy for 2026–2030, approved by the Cabinet in August 2026. Among its priorities are expanding efficient local production, ensuring internationally accepted quality standards and improving access to affordable essential medicines.
However, investment announcements alone cannot establish a sustainable pharmaceutical industry. Sri Lanka must develop reliable supplies of active pharmaceutical ingredients, specialised packaging, technical expertise, research facilities and internationally recognised quality-assurance systems.
Equally important is the transparency of commercial arrangements. Synergy’s detailed return-on-investment projections, financing structure, production costs and expected export earnings have not been publicly disclosed in the information available.
The Government must therefore establish measurable production targets, monitor import substitution and ensure that any procurement guarantees or incentives provide tangible benefits to taxpayers.
Sri Lanka’s pharmaceutical ambitions offer a valuable opportunity to combine industrial development with national health security. But the ultimate measure of success must be affordable medicines, dependable supplies, foreign-exchange savings and a competitive industry capable of earning export revenue.